A study using brain imaging and biomarker data identified three distinct patterns of cognitive decline in people with preclinical Alzheimer's disease.
Key Details
- 1Researchers analyzed 6-year data from the A4 and LEARN studies, involving people with preclinical Alzheimer's.
- 2Three cognitive trajectories were identified: stable, slow decline, and fast decline; 70% of participants remained stable.
- 3Higher baseline levels of phosphorylated tau (P-tau217) and brain scan tau markers, as well as smaller hippocampal volumes, predicted greater cognitive decline.
- 4Biomarker models could predict stable vs. declining status with about 70% accuracy.
- 5Findings suggest many clinical trial participants do not decline, complicating drug effect measurement.
Why It Matters
The study advances understanding of heterogeneity in Alzheimer's progression and highlights the potential for imaging biomarkers (e.g., PET, MRI) to inform prognosis and participant selection in clinical trials. Improved prediction via imaging and AI could optimize trial design and enable more personalized care in neurodegenerative disease.
Source
EurekAlert
Related News
•EurekAlert
AI Framework Accelerates Aortic Aneurysm Risk Prediction from Imaging
Researchers developed BioPINN-LM, combining physics-informed neural networks and multimodal large language models to deliver fast, interpretable risk assessments for ascending thoracic aortic aneurysms.
•EurekAlert
Study Finds Patient Voices Missing in Generative AI Design for Oncology
A Flinders University-led review found patients and carers are rarely involved in shaping generative AI tools used in oncology.
•EurekAlert
Scripps Researchers Develop AI Foundation Model for ECG-Based Heart Disease Prediction
A new AI foundation model, ECG-CLIP, improves detection and prediction of multiple heart diseases using large-scale ECG and clinician note data.